- DGAP-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
- DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
- DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
- DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
- DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
- DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
- DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
More ▼
Key statistics
As of last trade, MorphoSys AG (MOR:NSQ) traded at 5.78, 32.95% above the 52 week low of 4.35 set on May 12, 2022.
52-week range
Markit short selling activity
Open | 5.86 |
---|---|
High | 5.86 |
Low | 5.72 |
Bid | 5.76 |
Offer | 5.78 |
Previous close | 5.86 |
Average volume | 37.19k |
---|---|
Shares outstanding | 136.93m |
Free float | 136.91m |
P/E (TTM) | -- |
Market cap | 803.94m USD |
EPS (TTM) | -6.36 USD |
Data delayed at least 15 minutes, as of Aug 10 2022 16:07 BST.
More ▼